Inflammation is associated with the remodeling of calcific aortic valve disease

Inflammation

Volumn 36, Issue 3, 2013, Pages 573-581

  Coté, Nancy ^a   Mahmut, Ablajan ^a   Bosse, Yohan ^a   Couture, Christian ^a   Pagé, Sylvain ^a   Trahan, Sylvain ^a   Boulanger, Marie Chloé ^a   Fournier, Dominique ^a   Pibarot, Philippe ^a   Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

aortic stenosis; calcific aortic valve disease; inflammation; neovascularization; osseous metaplasia; remodelling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANGIOGENESIS; AORTA STENOSIS; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; ARTICLE; BONE METAPLASIA; CALCIFIC AORTIC VALVE DISEASE; CELL AGGREGATION; CELL DENSITY; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY INFILTRATE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METAPLASIA;

AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; DISEASE PROGRESSION; FEMALE; HEMODYNAMICS; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LIPIDS; MALE; NEOVASCULARIZATION, PATHOLOGIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877732914     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9579-6     Document Type: Article

References (22)

1. Cote, C., P. Pibarot, J.P. Despres, D. Mohty, A. Cartier, B.J. Arsenault, C. Couture, and P. Mathieu. 2008. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 94: 1175-1180.
2. Messika-Zeitoun, D., M.C. Aubry, D. Detaint, L.F. Bielak, P.A. Peyser, P.F. Sheedy, S.T. Turner, J.F. Breen, C. Scott, A.J. Tajik, and M. Enriquez-Sarano. 2004. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation 110: 356-362.
3. Mohty, D., P. Pibarot, J.P. Despres, C. Cote, B. Arsenault, A. Cartier, P. Cosnay, C. Couture, and P. Mathieu. 2008. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 187-193.
4. Rajamannan, N.M., F.J. Evans, E. Aikawa, K.J. Grande-Allen, L.L. Demer, D.D. Heistad, C.A. Simmons, K.S. Masters, P. Mathieu, K.D. O'Brien, F.J. Schoen, D.A. Towler, A.P. Yoganathan, and C.M. Otto. 2011. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease - 2011 update. Circulation 124: 1783-1791.
5. Cowell, S.J., D.E. Newby, R.J. Prescott, P. Bloomfield, J. Reid, D.B. Northridge, and N.A. Boon. 2005. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. The New England Journal of Medicine 352: 2389-2397.
6. Rossebo, A.B., T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Barwolf, I. Holme, Y.A. Kesaniemi, W. Malbecq, C.A. Nienaber, S. Ray, T. Skjaerpe, K. Wachtell, and R. Willenheimer. 2008. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. The New England Journal of Medicine 359: 1343-1356.
7. Chan, K.L., K. Teo, J.G. Dumesnil, A. Ni, and J. Tam. 2010. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation 121: 306-314.
8. Otto, C.M. 2008. Calcific aortic stenosis - time to look more closely at the valve. The New England Journal of Medicine 359: 1395-1398.
9. Warren, B.A., and J.L. Yong. 1997. Calcification of the aortic valve: its progression and grading. Pathology 29: 360-368.
10. Wypasek, E., J. Natorska, G. Grudzien, G. Filip, J. Sadowski, and A. Undas. 2012. Mast cells in human stenotic aortic valves are associated with the severity of stenosis. Inflammation. doi: 10.1007/s10753-012-9565-z.
11. Dweck, M.R., C. Jones, N.V. Joshi, A.M. Fletcher, H. Richardson, A. White, M. Marsden, R. Pessotto, J.C. Clark, W.A. Wallace, D.M. Salter, G. McKillop, E.J. van Beek, N.A. Boon, J.H. Rudd, and D.E. Newby. 2012. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 125: 76-86.
12. Yip, C.Y., and C.A. Simmons. 2011. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovascular Pathology 20: 177-182.
13. Charest, A., A. Pepin, R. Shetty, C. Cote, P. Voisine, F. Dagenais, P. Pibarot, and P. Mathieu. 2006. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 92: 1844-1849.
14. Mohler III, E.R., F. Gannon, C. Reynolds, R. Zimmerman, M.G. Keane, and F.S. Kaplan. 2001. Bone formation and inflammation in cardiac valves. Circulation 103: 1522-1528.
15. Briand, M., I. Lemieux, J.G. Dumesnil, P. Mathieu, A. Cartier, J.P. Despres, M. Arsenault, J. Couet, and P. Pibarot. 2006. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. Journal of the American College of Cardiology 47: 2229-2236.
16. Briand, M., P. Pibarot, J.P. Despres, P. Voisine, J.G. Dumesnil, F. Dagenais, and P. Mathieu. 2006. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 114: I512-I517.
17. Katz, R., N.D. Wong, R. Kronmal, J. Takasu, D.M. Shavelle, J.L. Probstfield, A.G. Bertoni, M.J. Budoff, and K.D. O'Brien. 2006. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113: 2113-2119.
18. Mathieu, P., I. Lemieux, and J.P. Despres. 2010. Obesity, inflammation, and cardiovascular risk. Clinical Pharmacology and Therapeutics 87: 407-416.
19. Mathieu, P., P. Poirier, P. Pibarot, I. Lemieux, and J.P. Despres. 2009. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 53: 577-584.
20. Kaden, J.J., R. Kilic, A. Sarikoc, S. Hagl, S. Lang, U. Hoffmann, M. Brueckmann, and M. Borggrefe. 2005. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. International Journal of Molecular Medicine 16: 869-872.
21. Bosse, Y., A. Miqdad, D. Fournier, A. Pepin, P. Pibarot, and P. Mathieu. 2009. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circulation. Cardiovascular Genetics 2: 489-498.
22. Derbali, H., Y. Bosse, N. Cote, P. Pibarot, A. Audet, A. Pepin, B. Arsenault, C. Couture, J.P. Despres, and P. Mathieu. 2010. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. American Journal of Pathology 176: 2638-2645.